Please login to the form below

Not currently logged in
Email:
Password:

Artios Pharma

This page shows the latest Artios Pharma news and features for those working in and with pharma, biotech and healthcare.

DNA damage specialists Artios Pharma raises $84m

DNA damage specialists Artios Pharma raises $84m

Team behind development of Lynparza focus on next-gen DDR inhibitors. Cambridge, UK-based Artios Pharma has raised $84 million (£65 million) in a series B financing. ... Artios’ existing shareholders Arix Bioscience, SV Health Investors, M Ventures,

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest appointments

  • Artios Pharma appoints science strategy VP Artios Pharma appoints science strategy VP

    Francis Crick Institute lead Dr Simon Boulton joins management team. Cambridge, UK-based Artios Pharma has appointed Dr Simon Boulton as vice president of science strategy. ... He brings over 20 years of expertise in DNA repair and the treatment of

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics